China Issues New Risk Classification Rule For GMP Inspections
This article was originally published in PharmAsia News
Executive Summary
The new risk-based regulation highlights recordkeeping and high-risk products with stricter enforcement for repeat offenders. Meanwhile, SFDA is also implementing an electronic monitoring system to improve drug safety.